PE20121643A1 - Polipeptidos del factor ix modificados y usos de los mismos - Google Patents

Polipeptidos del factor ix modificados y usos de los mismos

Info

Publication number
PE20121643A1
PE20121643A1 PE2012000114A PE2012000114A PE20121643A1 PE 20121643 A1 PE20121643 A1 PE 20121643A1 PE 2012000114 A PE2012000114 A PE 2012000114A PE 2012000114 A PE2012000114 A PE 2012000114A PE 20121643 A1 PE20121643 A1 PE 20121643A1
Authority
PE
Peru
Prior art keywords
polypeptide
remains
factor
polypeptides
conjugate
Prior art date
Application number
PE2012000114A
Other languages
English (en)
Spanish (es)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20121643A1 publication Critical patent/PE20121643A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2012000114A 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos PE20121643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
PE20121643A1 true PE20121643A1 (es) 2012-11-25

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000114A PE20121643A1 (es) 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461821A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013500726A (cg-RX-API-DMAC7.html)
KR (1) KR20120060209A (cg-RX-API-DMAC7.html)
CN (1) CN102573890A (cg-RX-API-DMAC7.html)
AU (1) AU2010278721A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002072A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769258A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000238A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120052A (cg-RX-API-DMAC7.html)
CU (3) CU20120018A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000030A (cg-RX-API-DMAC7.html)
EA (1) EA201290069A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011637A (cg-RX-API-DMAC7.html)
GT (1) GT201200023A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00908A (cg-RX-API-DMAC7.html)
MX (1) MX2012001346A (cg-RX-API-DMAC7.html)
PE (1) PE20121643A1 (cg-RX-API-DMAC7.html)
SG (1) SG178119A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011014890A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200716B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
SI3581650T1 (sl) 2008-09-15 2023-06-30 uniQuore biopharma B.V. Polipeptidni mutant faktorja IX, njegova uporaba in metoda za njegovo proizvodnjo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 血液凝固タンパク質複合体
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102269494B1 (ko) * 2010-07-30 2021-06-25 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CA2856492C (en) * 2011-12-19 2017-01-10 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
CN105121461A (zh) * 2013-03-13 2015-12-02 伊莱利利公司 修饰的犬瘦素多肽
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
EP3867380A2 (en) 2018-10-18 2021-08-25 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CU20130057A7 (es) 2013-06-28
CL2012000238A1 (es) 2012-10-05
IN2012DN00908A (cg-RX-API-DMAC7.html) 2015-04-03
CU20130058A7 (es) 2013-06-28
AU2010278721A1 (en) 2012-02-16
CA2769258A1 (en) 2011-02-03
US20120164130A1 (en) 2012-06-28
EA201290069A1 (ru) 2012-07-30
GT201200023A (es) 2014-01-27
MX2012001346A (es) 2012-02-17
ZA201200716B (en) 2013-07-31
EP2461821A1 (en) 2012-06-13
WO2011014890A1 (en) 2011-02-03
EP2461821A4 (en) 2013-07-03
DOP2012000030A (es) 2012-02-29
CN102573890A (zh) 2012-07-11
ECSP12011637A (es) 2012-02-29
CU20120018A7 (es) 2012-06-21
BR112012002072A2 (pt) 2016-11-08
KR20120060209A (ko) 2012-06-11
SG178119A1 (en) 2012-03-29
JP2013500726A (ja) 2013-01-10
CR20120052A (es) 2012-06-04

Similar Documents

Publication Publication Date Title
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
PE20091931A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
CO6351745A2 (es) Polipéptidos g-csf bovinos modificados y sus usos
DOP2010000311A (es) Polipeptidos modificados del factor ix y usos de los mismos
WO2010043650A3 (en) Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
AR084053A1 (es) Agente terapeutico que induce citotoxicidad
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
BR112012015461A2 (pt) polipeptídeos de somatotropina boviina modificados e seus usos
GT200900229A (es) Coagonistas de receptor de glucagón/glp-1
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
PE20120021A1 (es) Mutantes fgf21
AR092076A1 (es) Proteinas homodimericas
CL2008003694A1 (es) Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica.
EP4403197A3 (en) Injectable formulations for organ augmentation
CL2008000899A1 (es) Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas

Legal Events

Date Code Title Description
FC Refusal